ISA reports highlights of randomized Phase 2 cancer vaccine trial in head & neck cancer

12 Dec 2023

Study indicates clear route to market despite not meeting the primary endpoint of 6 months’ overall response rate (ORR) in the entire population

In a predefined subgroup of patients there was a doubling of ORR (51.9% vs 26.7% for placebo) and improved overall survival which sets the stage for a confirmatory Phase 3 trial

Oegstgeest, 12 December 2023 — ISA today announced positive anti-tumor response data with ISA101b, an HPV16 directed therapeutic cancer vaccine given in combination with Libtayo®, an anti-PD1 checkpoint inhibitor (CPI).  The data were generated in the OpcemISA trial, a large scale randomized double blind study that is ongoing

Read more »

ISA, in partnership with Erasmus MC, is awarded TKI grant and expands clinical pipeline

20 Jul 2021

Grant accelerates clinical development of immunotherapy to treat chronic hepatitis B virus infection

Oegstgeest, 20 July 2021 – ISA Pharmaceuticals B.V. is pleased to announce that a consortium between the Erasmus MC and ISA has been awarded a Private-Public Partnerships (PPP) Allowance made available by Health~Holland, Top Sector Life Sciences & Health, to conduct a first-in-human, phase 1 study of ISA104 to treat hepatitis B in chronically infected patients.

The clinical study, to be conducted in close collaboration with the Gastroenterology & Hepatology department of the Erasmus MC, is entitled the ‘HEB-PEP study’. The project starts in August 2021 and the clinical

Read more »

Vaccine-Chemo Combo Shows Promise in Treating Advanced, HPV-Associated Cervical Cancer

30 Mar 2020

Blog by Arthur N. Brodsky, PhD, published on Cancerresearch.org on 27 March 2020. Click here to access the original article.

Just weeks after International Human Papilloma Virus (HPV) Awareness
Day, new results
from two long-time Cancer Research Institute (CRI) scientists highlighted the
promise of immunotherapy against HPV-associated cervical cancer.

In a phase 1/2 study, women with advanced, recurrent, or
metastatic cervical cancer were treated with the combination of an
HPV-targeting vaccine and standard-of-care chemotherapy. Of 72 evaluable
patients, 43 percent had their tumors shrink.

Led by Cornelis J.
M. Melief, M.D, Ph.D., and Sjoerd H. van der Burg, Ph.D.,
this clinical breakthrough was the latest fruit borne by the duo, both of
whom have been supported

Read more »

ISA Pharmaceuticals announces CervISA publication

19 Mar 2020

Synergy between Synthetic Long Peptides (SLP®) immunotherapeutics and standard chemotherapy in late stage cancer including meaningful survival improvements in SLP immune responders

Leiden, The Netherlands, 19 March 2020 — ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, announces publication of its phase 2, CervISA study in the peer-reviewed journal “Science Translational Medicine”. The paper titled ‘Strong vaccine responses during chemotherapy are associated with prolonged survival’ can be found here.

The CervISA study was an open label, phase 2 study in patients with late stage HPV16 positive cervical cancer. Seventy-seven patients were treated with ISA Pharma’s lead product, ISA101b, an HPV16-specific immunotherapeutic

Read more »

ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank

13 Oct 2019

Financing
to boost late-stage development of novel therapy to treat life-threatening, virus-induced
cancersLoan supported
by the “InnovFin
–
EU-finance for innovators”
programme

The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16).

Persistent
HPV16 infection can cause cervical, head & neck and anogenital cancers.
These cancers can be severe and life-threatening, with low overall survival
rates of advanced stages. Cervical cancer is the 2nd most common
cancer in women aged 15 to 44 years in Europe, with HPV16 causing over 35,000
new cases and 15,000 deaths each year. The

Read more »